Cargando…

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease

Alzheimer’s disease (AD) is a severe neurodegenerative brain disorder. The determination of beta-amyloid (Aβ)-40, –42, total tau, and phospho-tau-181 (pTau181) in cerebrospinal fluid (CSF) using Lumipulse technology has been established as biomarkers for AD in recent years. As CSF collection is an i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marksteiner, Josef, Defrancesco, Michaela, Humpel, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557075/ https://www.ncbi.nlm.nih.gov/pubmed/36247998 http://dx.doi.org/10.3389/fnagi.2022.1014305

Ejemplares similares

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Phospho-Tau and Cognitive Decline in Alzheimer's Disease. Commentary: Tau in physiology and pathology
por: DeFelipe, Javier
Publicado: (2016)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy Subjects
por: Hochstrasser, Tanja, et al.
Publicado: (2011)

Differential Hyperphosphorylation of Tau-S199, -T231 and -S396 in Organotypic Brain Slices of Alzheimer Mice. A Model to Study Early Tau Hyperphosphorylation Using Okadaic Acid
por: Foidl, Bettina M., et al.
Publicado: (2018)

Western Agarose Native GeELution (WANGEL) with beta-amyloid and tau: Novel method to elute proteins or peptides using native agarose gels followed by Lumipulse assay
por: Korde, Dhwani S., et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy
por: Kimura, Taeko, et al.
Publicado: (2018)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Phospho-Tau and Chromatin Landscapes in Early and Late Alzheimer’s Disease
por: Gil, Laura, et al.
Publicado: (2021)

Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
por: Martínez-Dubarbie, Francisco, et al.
Publicado: (2023)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Platelet dysfunction in hypercholesterolemia mice, two Alzheimer’s disease mouse models and in human patients with Alzheimer’s disease
por: Plagg, Barbara, et al.
Publicado: (2015)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Telomere length is age-dependent and reduced in monocytes of Alzheimer patients
por: Hochstrasser, Tanja, et al.
Publicado: (2012)

Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer’s disease and PART
por: Kaufman, Sarah K., et al.
Publicado: (2018)

Use of Benzodiazepines in Alzheimer’s Disease: A Systematic Review of Literature
por: Defrancesco, Michaela, et al.
Publicado: (2015)

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain
por: DeVos, Sarah L., et al.
Publicado: (2018)

PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
por: Luna-Viramontes, Nabil Itzi, et al.
Publicado: (2020)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Tau kinetics in Alzheimer's disease
por: Hier, Daniel B., et al.
Publicado: (2022)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
por: Sanchez-Mejias, Elisabeth, et al.
Publicado: (2016)

Phospho-Tau Changes in the Human CA1 During Alzheimer’s Disease Progression
por: Regalado-Reyes, Mamen, et al.
Publicado: (2019)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimer’s disease
por: Merino-Serrais, Paula, et al.
Publicado: (2013)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease
por: Kalia, Vrinda, et al.
Publicado: (2023)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1dmmr03174so9bs43hakihm59k